🔥 3 Must-Buy Stocks Right Now—Top Analysts Reveal Their September 2025 Picks

Markets are moving—and these names lead the charge.

Wall Street’s sharpest minds just dropped their highest-conviction ideas. We break down the trio everyone’s talking about.

1. The AI Powerhouse Primed to Dominate

This tech titan isn’t just riding the AI wave—it’s building the ocean. Recent breakthroughs in inference efficiency have analysts scrambling to upgrade price targets. One major firm calls it 'the compute backbone of the next decade.'

2. The Energy Disruptor Changing the Game

Traditional utilities didn’t see this one coming. With regulatory tailwinds and a patented grid-storage solution, this stock’s poised to rally another 40%—or so the bulls claim. Shorts are getting squeezed. Hard.

3. The Biotech Breakout Nobody Expected

Phase 3 data shocked the street. Now this under-the-radar innovator’s pipeline has Big Pharma circling. One top analyst says it’s 'not a question of if, but when' a buyout offer lands.

Sure, past performance doesn’t guarantee future results—but in a market this hungry for growth, these three stocks offer more than just hope. They offer a plan. Even if half of Wall Street’s price targets are just fancy guesswork dressed in a suit.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

(RZLV) – Rezolve AI is a UK-based company providing generative AI solutions for retail and e-commerce. Yesterday, Northland Securities analyst Michael Latimore maintained a Buy rating on the stock with a price target of $5 per share. Interestingly, four out of the five Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 54.88%. 

(IMVT) – Immunovant is a clinical-stage biotech developing antibody therapies for autoimmune diseases. Yesterday, LifeSci Capital analyst Sam Slutsky maintained a Buy rating on the stock with a price target of $50 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 155.51%.

(IVA) – Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for fibrosis, rare diseases, and related conditions. Yesterday, H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on the stock with a price target of $20 per share. In the last three months, all six Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 232.76%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.